Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Assays, among those commercially available, to measure rivaroxaban pharmacodynamics, found one-step PiCT and HepTest with shortened incubation times, as well as the widely available PT assay could be useful to monitor the pharmacodynamic effects of rivroxaban accurately. Expand
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women, and data suggest that transder mal ERT might be safer than oral ERT with respect to thrombotic risk. Expand
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study
Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk. Expand
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment, and transdermal oestrogens may be safer with respect to thrombotic risk. Expand
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
- P. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, M. Aiach
- Arteriosclerosis, thrombosis, and vascular…
- 1 November 1997
Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Expand
Risk assessment for recurrent venous thrombosis
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials. Expand
Progestogen-only contraception in women at high risk of venous thromboembolism.
- J. Conard, G. Plu-Bureau, Narges Bahi, M. Horellou, C. Pélissier, J. Thalabard
- 1 December 2004
Using the Cox model to adjust for confounding variables such as age, thrombophilia and body mass index, the relative risk of VTE associated with the use of CMA was not significant and reassuring results need to be confirmed in other prospective studies. Expand
Estrogen plus progestin and risk of venous thrombosis.
Hormonal contraceptives and venous thromboembolism: an epidemiological update.
- G. Plu-Bureau, L. Maitrot-Mantelet, J. Hugon-Rodin, M. Canonico
- Best practice & research. Clinical endocrinology…
- 1 February 2013
In the context of contraceptive use, non-oral route of ethinyl-estradiol administration seems to be more thrombogenic than oral route, and low doses of both oral progestin contraceptives and intrauterine levonorgestrel could be safe with respect to VTE risk. Expand